Success Metrics

Clinical Success Rate
80.0%

Based on 20 completed trials

Completion Rate
80%(20/25)
Active Trials
4(10%)
Results Posted
35%(7 trials)
Terminated
5(12%)

Phase Distribution

Ph phase_4
5
12%
Ph phase_1
2
5%
Ph not_applicable
8
19%
Ph phase_2
15
36%
Ph phase_3
9
21%

Phase Distribution

2

Early Stage

15

Mid Stage

14

Late Stage

Phase Distribution39 total trials
Phase 1Safety & dosage
2(5.1%)
Phase 2Efficacy & side effects
15(38.5%)
Phase 3Large-scale testing
9(23.1%)
Phase 4Post-market surveillance
5(12.8%)
N/ANon-phased studies
8(20.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

20 of 28 finished

Non-Completion Rate

28.6%

8 ended early

Currently Active

4

trials recruiting

Total Trials

42

all time

Status Distribution
Active(4)
Completed(20)
Terminated(8)
Other(10)

Detailed Status

Completed20
unknown10
Terminated5
Recruiting4
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
42
Active
4
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (5.1%)
Phase 215 (38.5%)
Phase 39 (23.1%)
Phase 45 (12.8%)
N/A8 (20.5%)

Trials by Status

withdrawn37%
completed2048%
recruiting410%
unknown1024%
terminated512%

Recent Activity

4 active trials
Showing 5 of 42
recruitingphase_2

Promoting Recovery After STroke With Amantadine

NCT05140148
recruiting

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

NCT04367883
recruiting

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

NCT05504057
completedphase_2

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244
withdrawnphase_2

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

NCT06234462
View all 42 trials

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT05140148Phase 2

Promoting Recovery After STroke With Amantadine

Recruiting
NCT04367883

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Recruiting
NCT05504057

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

Recruiting
NCT06055244Phase 2

Amantadine Therapy for Cognitive Impairment in Long COVID

Completed
NCT06234462Phase 2

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Withdrawn
NCT07113015Not Applicable

A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease

Completed
NCT03430817Phase 4

Citicholine-Amantadine Trial in Traumatic Brain Injury

Completed
NCT05479032Phase 2

Amantadine for Neuroenhancement in Acute Patients Study

Recruiting
NCT04936126Phase 4

Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Unknown
NCT01071395Phase 4

Validation of Dyskinesia Rating Scales

Completed
NCT05667077Phase 2

The Effect of Amantadine on Post-COVD-19 Fatigue

Unknown
NCT04952519Phase 3

Efficacy of Amantadine Treatment in COVID-19 Patients

Terminated
NCT00800514Not Applicable

Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)

Withdrawn
NCT00627250Not Applicable

Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability

Completed
NCT04894617Phase 3

Amantadine for COVID-19

Unknown
NCT02277938

Acetylamantadine Excretion by Cancer Patients

Unknown
NCT01538329Phase 2

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Completed
NCT03185065Phase 3

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

Completed
NCT02025439Not Applicable

Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness

Completed
NCT02486211Phase 2

Amantadine to Speed Awakening After Cardiac Arrest

Completed

Drug Details

Intervention Type
DRUG
Total Trials
42